UPSTREAM BIO, INC. (UPB) Reports the reporting period Financial Results
UPSTREAM BIO, INC. (UPB) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 668
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 101578
Phase 3 Strategy for High
Dose Quarterly Administration in Broad Patient Populations in Severe Asthma and CRSwNP Supported by Analyses of Phase 2 Trial ResultsoEvaluation of exposure
response relationships across multiple clinical endpoints in both severe asthma and CRSwNP supports the Company’s intent to study a high
📋 UPSTREAM BIO, INC. (UPB) - Financial Results
Filing Date: 2026-03-26
Accepted: 2026-03-26 07:05:07
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: